<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04122937</url>
  </required_header>
  <id_info>
    <org_study_id>AS0003</org_study_id>
    <nct_id>NCT04122937</nct_id>
  </id_info>
  <brief_title>Defining Inflammation Related to Peritoneal Carcinomatosis in Women With Ovarian or Colon Cancer.</brief_title>
  <acronym>CarFlog</acronym>
  <official_title>Molecular Characterisation and Clinical Implications of Inflammation Related to Peritoneal Carcinomatosis in Women With Ovarian or Colon Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation plays an important role in the pathogenesis of peritoneal carcinosis. Patients
      with elevated levels of different inflammation cytokines show a worse prognosis at the time
      of diagnosis. In women, ovarian and colon cancer are the main causes of peritoneal carcinosis
      and a comparison of these two different types of peritoneal invasion have not been conducted
      yet. We found interesting studying the role of immune response, in particular
      tumour-associated antigens (TAA) that modulate the metastatic process. We will investigate
      also mitochondrial defects, such as mutations in mt-DNA, potentially involved in
      carcinogenesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the time of hospitalization all the patients will undergo a complete clinical evaluation
      with determination of biochemical parameters such as fasting blood glucose, blood count,
      hs-CRP, AST and ALT, uric acid, creatinine and BUN. An extra blood aliquot will be collected
      to assess the serum biomarkers under investigation.

      During surgery two samples of peritoneal tissue macroscopically undamaged will be collected.
      On those samples will be executed separation of adipocytes cells, RNA and protein extraction
      for measuring of inflammatory and neoplastic biomarkers, determination of P2X7R-inflammasome
      activity and mitochondrial DNA analyse.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">March 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Immune biomarkers level</measure>
    <time_frame>Each patients will be assessed at baseline</time_frame>
    <description>Serum level of different immune related biomarkers (such as CD4, CD8, CUZD1, LAG3, PD1, PDL1, IMP1 and p62/IMP2) will be determined using ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metastatic mediators level</measure>
    <time_frame>Each patients will be assessed at baseline</time_frame>
    <description>Peritoneal expression of cytokines related to metastatic process (such as IL6, IL2, TNFα, TGFβ1, VEGF, CD68, FGFR1, CCL2/MCP-1, CD73) will be determined using real time-PCR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>P2X7R-inflammasome activity</measure>
    <time_frame>Each patients will be assessed at baseline</time_frame>
    <description>Peritoneal expression of NLRP3-ASC will be determine using RT-PCR</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <description>Patients affected by ovarian cancer will be stratified according to BRCA1 and BRCA2 mutational status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colon cancer</arm_group_label>
    <description>Patients affected by colon cancer will be similarly stratified according to BRAF and KRAS mutational status and to the presence of low-grade or high-grade microsatellite instability (MSI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreductive surgery</intervention_name>
    <description>Partial removal of peritoneal tissue involved by neoplastic invasion</description>
    <arm_group_label>Colon cancer</arm_group_label>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <other_name>Debulking</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peritoneal biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study consecutively enrolled 30 patients undergoing surgical treatment for peritoneal
        carcinosis: 15 patients affected by high grade ovarian cancer and 15 patients affected by
        colon cancer. Patients will be enrolled among those referring to the Gynaecologic Unit and
        the General Surgery Unit, University Hospital of Pisa, Italy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological diagnosis of peritoneal carcinosis secondary to colon cancer or
             high-grade ovarian cancer

          -  patients able to consent

        Exclusion Criteria:

          -  previous malignancies, except for patients with cutaneous basal cell carcinoma,
             Cervical Intraepithelial Neoplasia (CIN) or melanoma in situ

          -  current chemotherapy or radiotherapy

          -  current steroid therapy or immunotherapy

          -  patients affected by systemic inflammatory disease and/or Inflammatory bowel disease
             (IBD)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Solini, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Anna Solini</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>peritoneal carcinomatosis</keyword>
  <keyword>colon cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>P2X7R-inflammasome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

